<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870879</url>
  </required_header>
  <id_info>
    <org_study_id>AOP1840</org_study_id>
    <nct_id>NCT04870879</nct_id>
  </id_info>
  <brief_title>Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors</brief_title>
  <acronym>MELODIC</acronym>
  <official_title>Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors: an Inductive Padova Center Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MELODIC trial is an prospective, multicenter, non-randomized, open-label, parallel trial,&#xD;
      aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation&#xD;
      (LT) in unresecable CRC liver-only metastases, compared with a matched cohort of patients&#xD;
      bearing the same tumor characteristics, and treated with chemotherapy. Synthesis of Inclusion&#xD;
      parameters: &quot;10;10;10;100&quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will compared survival in patient enrolled in the MELODIC trial with the OS in a matched cohort of patients treated with chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of drop out</measure>
    <time_frame>within liver transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>90 days after liver transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Colorectal Liver Metastases</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Unresectable Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parallel arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Transplant</intervention_name>
    <description>Liver Transplant from cadaveric donors</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Parallel arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Sythesis: 10;10;10;100):&#xD;
&#xD;
          -  â‰¥ 18 and &lt;70 years&#xD;
&#xD;
          -  Performance status, ECOG 0-1&#xD;
&#xD;
          -  Histologically proved adenocarcinoma in colon or rectum.&#xD;
&#xD;
          -  BRAF wild-type CRC on primary tumor or liver metastases&#xD;
&#xD;
          -  High standard oncological surgical resection of the primary tumor&#xD;
&#xD;
          -  Liver metastases not eligible for curative liver resection confirmed by the validation&#xD;
             committee&#xD;
&#xD;
          -  At least one line (3 months) of chemotherapy&#xD;
&#xD;
          -  No signs of extra hepatic metastatic disease or local recurrence on CT, MRI and Pet-CT&#xD;
             within 4 weeks prior to the faculty meeting at the transplant unit&#xD;
&#xD;
          -  Before start of chemotherapy no lesion should be larger than &gt; 10 cm&#xD;
&#xD;
          -  Objective response according to RECIST 1.1 or SD at two consecutive CT without CEA&#xD;
             increase&#xD;
&#xD;
          -  Patient with less than 10% response on chemotherapy may be included if they obtain al&#xD;
             least 20% response after TACE (DEB-IRI) or by 90Y-spheres&#xD;
&#xD;
          -  At least 10 months time span from CRC resection and date of being listed on the&#xD;
             transplantation list.&#xD;
&#xD;
          -  Satisfactory blood tests Hb &gt;10g/dL, neutrophils &gt;1.0, Bilirubin&lt;2 x upper normal&#xD;
             level, AST, ALT&lt;5 x upper normal level, creatinine and albumin in normal level.&#xD;
&#xD;
          -  CEA&lt;100 ng/ml&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight loss &gt;10% the last 6 months&#xD;
&#xD;
          -  Patient BMI &gt; 30&#xD;
&#xD;
          -  Participation refusal&#xD;
&#xD;
          -  General contraindication to LT&#xD;
&#xD;
          -  Prior extra hepatic metastatic disease or primary tumor local relapse.&#xD;
&#xD;
          -  Other malignancies in the previous 5 years&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.O.C Chirurgia Epatobiliare e dei Trapianti Epatici, AOPD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umberto Cillo, MD</last_name>
    <phone>049.8212211-1897</phone>
    <email>cillo@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Lonardi, MD</last_name>
    <email>sara.lonardi@iov.veneto.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O.C Chirurgia Epatobiliare e Trapianti Epatici, Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Cillo, MD</last_name>
      <email>cillo@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Umberto Cillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

